Senolytics vs. NAD+ Boosters for Older Dogs: What the Label Evidence Actually Supports

By John Langlois, DVM, MSTCVM, CVA, CVMMP

Comparisons · August 21, 2026 · 7 min read

Senolytics and NAD+ boosters solve different cellular problems, and knowing which one your dog actually has changes what's worth buying.

Maren was a twelve-year-old German Shepherd who used to meet me at the clinic door with her whole back end wagging. Her owner brought her in on a Tuesday in February because that greeting had quietly stopped happening sometime over the winter. Maren still walked fine. Stairs were no problem. She just seemed to be running on a lower battery, slower to get up from the exam room floor, sleeping through most of the afternoon, less interested in the treat jar. Bloodwork was unremarkable. This is the visit that made me start reading the senolytic and NAD+ literature seriously, because “generalized cellular fatigue” isn’t a diagnosis I can bill for, and it isn’t one either ingredient class alone fully explains.

That distinction matters more than the marketing on either side wants it to. Senolytics and NAD+ boosters get bundled together constantly under a “longevity supplement” umbrella, and I understand why: both target processes tied to canine aging, both show up in the same product categories, and both are being sold to owners of dogs like Maren. But they are not solving the same problem, and a dog can genuinely need one, the other, or realistically some balance of both.

What senescent cells and NAD+ decline actually have in common — not much

Cellular senescence is what happens when a cell stops dividing but doesn’t die. It sits there instead, secreting inflammatory signaling molecules in what researchers call the senescence-associated secretory phenotype, or SASP. Senescent cells accumulate with age and are thought to contribute to the low-grade, chronic inflammation seen in older dogs and people alike. Senolytics are compounds meant to selectively clear those senescent cells out.

NAD+ decline is a different mechanism entirely. Nicotinamide adenine dinucleotide is a coenzyme every cell needs for energy metabolism and DNA repair, and its levels measurably drop with age. NAD+ boosters, usually nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), are precursors the body converts into NAD+ rather than NAD+ itself, since the intact molecule doesn’t cross cell membranes well. A review in Cellular and Molecular Life Sciences lays out both the therapeutic rationale for NR supplementation and its real limitations, including inconsistent uptake and the fact that raising blood NAD+ levels doesn’t automatically translate into a clinical outcome you can see in an exam room.

So one class is trying to remove a source of chronic inflammation. The other is trying to restore a fuel and repair molecule that’s running low. A dog can have plenty of senescent cell burden and still have decent NAD+ status, or the reverse. This is exactly the kind of distinction I try to walk owners through before they buy either category off a shelf display near the register.

What the actual dog trial measured, and what it didn’t

The most relevant data point I can point owners to is a randomized, controlled clinical trial that paired a senolytic with an NAD+ precursor in the same formula and tested it in senior dogs with mild to moderate cognitive impairment. The study, PMC (National Library of Medicine): A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination, enrolled roughly seventy dogs across placebo, low-dose, and full-dose groups and used owner-reported cognitive assessments as the primary outcome.

That framing matters. It’s a combination study, not a senolytic-alone or NAD+-alone comparison, so it can’t tell us which half of the formula did the work, or whether the two ingredients need each other to produce the effect at all. It also relied on owner-assessed scoring rather than an objective biomarker, which is a real limitation, not a disqualifying one. Owner-reported cognitive change is still clinically meaningful; it’s just not the same as a blinded cognitive test battery or a measured senescent-cell count. I want owners to know both things: this is genuine, published, peer-reviewed evidence in dogs, and it’s also one trial testing one specific combination at one specific center.

Rapamycin deserves a mention here because it gets lumped into “anti-aging supplement” conversations it doesn’t belong in. Rapamycin is an mTOR inhibitor, not a senolytic and not an NAD+ precursor, and it’s a prescription drug being studied through the Dog Aging Project’s Tufts Cummings School of Veterinary Medicine: Dog Aging Project Test of Rapamycin in Aging Dogs (TRIAD) trial at Tufts, not something in a chewable on a shelf. I bring it up only so owners stop conflating three different mechanisms into one “longevity pill” category. They are not interchangeable, and a supplement label that implies otherwise is doing more marketing than science.

The counterargument I take seriously

The strongest pushback I hear, usually from other practitioners, is that we’re years away from knowing whether clearing senescent cells or restoring NAD+ actually extends healthy lifespan in dogs the way it appears to in shorter-lived lab models. That’s a fair point, and I don’t dismiss it. Most of the deepest mechanistic work on senolytics and NAD+ metabolism still comes from rodent and cell-culture studies. The dog-specific trial data is real but thin, and a single combination trial with owner-reported outcomes is not the same weight of evidence as a decade of veterinary cardiology or oncology research.

I still land on recommending owners understand and consider this category for the right dog, for one reason: the downside risk profile, at labeled doses of a NASC-member product, is low compared to the plausible upside for a dog whose owner is already describing the kind of change Maren’s owner described to me. I’m not promising reversal of aging. I’m saying the biological rationale is sound, the safety data on NR and NMN at conservative doses is reassuring, and the one controlled dog trial we have showed a real, measured direction of effect.

Where whole-patient balance actually changes the recommendation

In my TCVM training, we talk about aging less as a single failing system and more as a gradual loss of balance across the whole patient, energy, circulation, digestion, sleep, mood, all interacting. I bring that lens into how I counsel owners on cellular-aging supplements, because a bottle of NAD+ precursor is not going to fix a dog whose real problem is untreated joint pain keeping her from moving enough to support her own metabolism, and a senolytic isn’t going to fix a dog whose real problem is a diet that’s quietly inflammatory on its own. I had an eleven-year-old Labrador mix, Otto, sixty-eight pounds, whose owner wanted to start him on a NAD+ chew because he’d “slowed down.” When we actually walked through his history, that slowdown tracked almost exactly with him no longer wanting to jump into the car, which pointed to hips before it pointed to mitochondria. We started with acupuncture and a joint-support plan, not a cellular-aging supplement, and his energy came back within about six weeks. The supplement conversation came later, once the more obvious explanation was addressed.

That’s the practical filter I use. If an older dog is genuinely healthy on exam, mobile, eating well, sleeping normally, and the owner is describing something closer to Maren’s low-grade fatigue than to a specific pain or mobility complaint, that’s the profile where a senolytic, an NAD+ precursor, or a combination formula has room to actually do something useful. If there’s an underlying pain, GI, or orthopedic issue driving the fatigue, that gets addressed first. It’s worth reading our Arthritis vs. Normal Aging Stiffness in Dogs piece if stiffness is part of what you’re seeing, because that distinction changes the whole plan before a cellular-aging ingredient is even relevant.

Reading the label either way

If you’re comparing products in this space, several real players are worth knowing by name, not because I’m ranking them, but because the category is genuinely crowded and inconsistent. Leap Years markets an NAD+ and senolytic combination with published research behind it. Zesty Paws sells an NAD+ formula built on a licensed NMN ingredient. LongTails uses a nicotinamide riboside dose in a collagen chew format. ThorneVET and Forever Dog Lab both sell into the broader senior cellular-health space without necessarily being pure NAD+ SKUs, and La Petite Labs is active in this category as well. None of that matters as much as what’s actually on the panel.

Check for the specific compound named, NR or NMN rather than a vague “NAD+ complex,” the milligram dose per serving rather than a proprietary blend, and, ideally, National Animal Supplement Council membership, which means the company has passed a third-party audit covering sourcing, quality control, and adverse event reporting. Format matters too, and it’s worth a look at our Chew vs Powder vs Liquid Supplements for Dogs comparison if you’re weighing whether your dog will actually take a given delivery format consistently, since a perfect dose that gets spit out on the kitchen floor helps nobody.

The verdict from someone who watches this category closely

I don’t think most senior dogs need both a senolytic and an NAD+ precursor simultaneously, and I don’t think either ingredient class replaces a real orthopedic or pain workup. What I do think is that the science on both mechanisms is legitimate, the one combination trial in dogs showed a real signal on owner-assessed cognition, and for a dog whose only complaint is that low-grade “running slower” feeling, a properly dosed, NASC-audited product in this category is a reasonable thing to try, not a false promise. Maren’s owner ended up starting with an orthopedic and dental workup first, the way I recommend for most dogs her age, and we revisited a cellular-aging supplement afterward, once we’d ruled out the more obvious explanations. That order of operations is the actual lesson here, more than which molecule wins.